PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-115.67%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-133.51%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-132.80%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-132.80%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.94%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
31.94%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-162.45%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-162.45%
Negative 5Y OCF/share CAGR while AGEN is at 51.82%. Joel Greenblatt would question the firm’s operational model or cost structure.
-162.45%
Negative 3Y OCF/share CAGR while AGEN stands at 60.54%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-7367.52%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-7367.52%
Negative 5Y net income/share CAGR while AGEN is 44.69%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-7367.52%
Negative 3Y CAGR while AGEN is 49.74%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-772.82%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-772.82%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-772.82%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Negative asset growth while AGEN invests at 35.21%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-61.26%
We have a declining book value while AGEN shows 35.11%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
8.45%
Debt growth of 8.45% while AGEN is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
We cut SG&A while AGEN invests at 41.36%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.